News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Filip Surmont, MD

Advertisement

Articles by Filip Surmont, MD

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

ByAlexander Bedenkov, MD, PhD,Andrey Ipatov, MD,Filip Surmont, MD,Carmen Moreno,Maarten Beekman, MD,Ryan Bate
October 11th 2019

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.

Advertisement

Latest Updated Articles

  • Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations
    Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

    Published: October 11th 2019 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

2

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

3

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

4

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships

5

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us